Is low-grade serous ovarian cancer part of the tumor spectrum of Hereditary Breast and Ovarian Cancer?

被引:26
作者
Vineyard, Marisa A. [2 ]
Daniels, Molly S. [1 ]
Urbauer, Diana L. [3 ]
Deavers, Michael T. [4 ]
Sun, Charlotte C. [1 ]
Boerwinkle, Eric [5 ]
Bodurka, Diane C. [1 ]
Gershenson, David M. [1 ]
Crawford, Jessica [1 ]
Lu, Karen H. [1 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Dept Gynecol Oncol, Houston, TX 77030 USA
[2] Univ Texas Hlth Sci Ctr, Houston Grad Sch Biomed Sci, Houston, TX 77030 USA
[3] Univ Texas MD Anderson Canc Ctr, Dept Biostat, Houston, TX 77030 USA
[4] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA
[5] Univ Texas Sch Publ Hlth, Houston, TX 77030 USA
关键词
Ovarian cancer; Low grade histopathology; BRCA1; BRCA2; Risk assessment; Hereditary breast and ovarian cancer; MUTATIONAL ANALYSIS; BRCA2; MUTATIONS; GERMLINE BRCA1; CARCINOMAS; FAMILIES; WOMEN;
D O I
10.1016/j.ygyno.2010.10.033
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective. To determine whether women with low-grade serous ovarian cancer (LGSOC) have personal and family histories of breast and ovarian cancer that are less suggestive of Hereditary Breast and Ovarian Cancer (HBOC), as compared to women with high-grade serous ovarian cancer (HGSOC). Methods. A single institution, case-control retrospective review of medical records was conducted. Personal demographics, personal cancer history, and family history of breast and ovarian cancer of women with LGSOC were collected and compared to controls with HGSOC, which is known to be associated with HBOC. Results. 195 cases of LGSOC and 386 controls-with HGSOC were included in the analysis. Women with LGSOC were significantly less likely to have a first- or second-degree relative with breast or ovarian cancer (p = 0.0016). Additionally, when the personal and family histories were quantified using the AMyriad BRC mutation prevalence tables, women with LGSOC had lower scores indicative of a less suggestive family history for HBOC (p = 0.027). Conclusions. In this study, women with LGSOC had family histories that were less suggestive of HBOC compared to women with HGSOC, especially when the degree of relatedness of affected relatives was taken into account. By beginning to determine if LGSOC is part of the tumor spectrum seen in HBOC, this study is an important step towards refining hereditary cancer risk assessment for women with ovarian cancer. (C) 2010 Elsevier Inc. All rights reserved.
引用
收藏
页码:229 / 232
页数:4
相关论文
共 21 条
[1]   Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary. [J].
Bonome, T ;
Lee, JY ;
Park, DC ;
Radonovich, M ;
Pise-Masison, C ;
Brady, J ;
Gardner, GJ ;
Hao, K ;
Wong, WH ;
Barrett, JC ;
Lu, KH ;
Sood, AK ;
Gershenson, DM ;
Mok, SC ;
Birrer, MJ .
CANCER RESEARCH, 2005, 65 (22) :10602-10612
[2]   Clinicopathologic features of BRCA-linked and sporadic ovarian cancer [J].
Boyd, J ;
Sonoda, Y ;
Federici, MG ;
Bogomolniy, F ;
Rhei, E ;
Maresco, DL ;
Saigo, PE ;
Almadrones, LA ;
Barakat, RR ;
Brown, CL ;
Chi, DS ;
Curtin, JP ;
Poynor, EA ;
Hoskins, WJ .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2000, 283 (17) :2260-2265
[3]   Demographic and genetic characteristics of patients with borderline ovarian tumors as compared to early stage invasive ovarian cancer [J].
Gotlieb, WH ;
Chetrit, A ;
Menczer, J ;
Hirsh-Yechezkel, G ;
Lubin, F ;
Friedman, E ;
Modan, B ;
Ben-Baruch, G .
GYNECOLOGIC ONCOLOGY, 2005, 97 (03) :780-783
[4]   Rates of Jewish ancestral mutations in BRCA1 and BRCA2 in borderline ovarian tumors [J].
Gotlieb, WH ;
Freidman, E ;
Bar-Sade, RB ;
Kruglikova, A ;
Hirsh-Yechezkel, G ;
Modan, B ;
Inbar, M ;
Davidson, B ;
Kopolovic, J ;
Novikov, I ;
Ben-Baruch, G .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1998, 90 (13) :995-1000
[5]   Toward understanding the natural history of ovarian carcinoma development: a clinicopathological approach [J].
Horiuchi, A ;
Itoh, K ;
Shimizu, M ;
Nakai, I ;
Yamazaki, T ;
Kimura, K ;
Suzuki, A ;
Shiozawa, I ;
Ueda, N ;
Konishi, I .
GYNECOLOGIC ONCOLOGY, 2003, 88 (03) :309-317
[6]   Early events in the pathogenesis of epithelial ovarian cancer [J].
Landen, Charles N., Jr. ;
Birrer, Michael J. ;
Sood, Anil K. .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (06) :995-1005
[7]   Grading ovarian serous carcinoma using a two-tier system [J].
Malpica, A ;
Deavers, MT ;
Lu, K ;
Bodurka, DC ;
Atkinson, EN ;
Gershenson, DM ;
Silva, EG .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2004, 28 (04) :496-504
[8]  
Myriad Genetic Laboratories, MUT PREV TABL
[9]   BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases [J].
Pal, T ;
Permuth-Wey, J ;
Betts, JA ;
Krischer, JP ;
Fiorica, J ;
Arango, H ;
LaPolla, J ;
Hoffman, M ;
Martino, MA ;
Wakeley, K ;
Wilbanks, G ;
Nicosia, S ;
Cantor, A ;
Sutphen, R .
CANCER, 2005, 104 (12) :2807-2816
[10]   Validity of models for predicting BRCA1 and BRCA2 mutations [J].
Parmigiani, Giovanni ;
Chen, Sining ;
Iversen, Edwin S., Jr. ;
Friebel, Tara M. ;
Finkelstein, Dianne M. ;
Anton-Culver, Hoda ;
Ziogas, Argyrios ;
Weber, Barbara L. ;
Eisen, Andrea ;
Malone, Kathleen E. ;
Daling, Janet R. ;
Hsu, Li ;
Ostrander, Elaine A. ;
Peterson, Leif E. ;
Schildkraut, Joellen M. ;
Isaacs, Claudine ;
Corio, Camille ;
Leondaridis, Leoni ;
Tomlinson, Gail ;
Amos, Christopher I. ;
Strong, Louise C. ;
Berry, Donald A. ;
Weitzel, Jeffrey N. ;
Sand, Sharon ;
Dutson, Debra ;
Kerber, Rich ;
Peshkin, Beth N. ;
Euhus, David M. .
ANNALS OF INTERNAL MEDICINE, 2007, 147 (07) :441-450